Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab-Reference-Cited by-同舟云学术

Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab

Published:2018-03-20 Issue:8 Volume:32 Page:1869-1873
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Gentile Massimo^ORCID,Shanafelt Tait D.,Reda Gianluigi,Mauro Francesca Romana,Zirlik Katja,Ciolli Stefania,Laurenti Luca,Del Principe Maria Ilaria,Rossi Davide,Di Renzo Nicola,Molica Stefano,Angrilli Francesco,Coscia Marta,Chiarenza Annalisa,Giordano Annamaria,Cutrona Giovanna^ORCID,Chaffee Kari G.^ORCID,Parikh Sameer A.,Uccello Giuseppina,Innocenti Idanna,Tripepi Giovanni,D’Arrigo Graziella,Vigna Ernesto,Recchia Anna Grazia,Herishanu Yair,Shvidel Lev,Tadmor Tamar,Cortelezzi Agostino,Del Poeta Giovanni,Gaidano Gianluca,Di Raimondo Francesco,Neri Antonino,Ferrarini Manlio,Foà Robin,Polliack Aaron,Morabito Fortunato

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-018-0100-6.pdf

Reference18 articles.

1. Eichhorst B, Hallek M. Prognostication of chronic lymphocytic leukemia in the era of new agents. Hematol Am Soc Hematol Educ Program. 2016;1:149–55.

2. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–74.

3. Fischer K, Cramer P, Busch R, Böttcher S, Bahlo J, Schubert J, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30:3209–16.

4. Thompson PA, Tam CS, O’Brien SM, Wierda WG, Stingo F, Plunkett W, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127:303–9.

5. Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127:208–15.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases;European Journal of Haematology;2021-01-28

2. Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?;Cells;2021-01-07

3. Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients;Scientific Reports;2020-10-28

4. Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?;Frontiers in Oncology;2020-10-28

5. TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors;Expert Opinion on Investigational Drugs;2020-06-27